GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Liabilities-to-Assets

Vincerx Pharma (Vincerx Pharma) Liabilities-to-Assets : 1.06 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Vincerx Pharma's Total Liabilities for the quarter that ended in Mar. 2024 was $11.71 Mil. Vincerx Pharma's Total Assets for the quarter that ended in Mar. 2024 was $11.08 Mil. Therefore, Vincerx Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 1.06.


Vincerx Pharma Liabilities-to-Assets Historical Data

The historical data trend for Vincerx Pharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Liabilities-to-Assets Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
- 0.60 0.15 0.20 0.38

Vincerx Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.32 0.40 0.38 1.06

Competitive Comparison of Vincerx Pharma's Liabilities-to-Assets

For the Biotechnology subindustry, Vincerx Pharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vincerx Pharma's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's Liabilities-to-Assets falls into.



Vincerx Pharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Vincerx Pharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=6.995/18.217
=0.38

Vincerx Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=11.705/11.083
=1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vincerx Pharma  (NAS:VINC) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Vincerx Pharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Vincerx Pharma (Vincerx Pharma) Business Description

Traded in Other Exchanges
N/A
Address
260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.
Executives
Alexander A. Seelenberger officer: Chief Financial Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi director, 10 percent owner, officer: Chief Operations Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy director, 10 percent owner, officer: President and CEO 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas officer: See Remarks 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe director 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang officer: Chief Business Officer 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang officer: Chief Technology Officer 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens director 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus officer: Chief Medical Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd 10 percent owner 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054

Vincerx Pharma (Vincerx Pharma) Headlines

From GuruFocus

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 06-16-2022

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 06-26-2022

Vincerx Pharma Provides Key Strategic Update

By GuruFocusNews GuruFocusNews 07-06-2022

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-06-2023